This presents CBX7 as a particularly attractive target for pharmacological intervention because its expression correlates with active phases of the CCM pathology, and inhibitory drugs are readily available (Ren et al, 2015, 2016). This evidence concerns the gene CBX7 and cerebral cavernous malformation.